Earlier studies have reported increased rates of Raynaud’s, decreased rates of cutaneous ulceration, milder muscle weakness and lower AST levels in JDM patients with anti-TIF1γ-associated autoantibodies [11, 12]. Here, TRIM33 is linked to juvenile dermatomyositis.